Dear Editor, We read with interest a recent paper by Buddhachat et al. (Buddhachat et al., 2017) who evaluated three marine lipid sources (fish oil, krill oil and green-lipped mussel oil) in an in vitro cartilage degradation model and who then concluded with a clinical recommendation as to the relative efficacy of these lipid substances. Putting aside whether the model used in this paper is appropriate in terms of the substances tested, a basic error was made in the comparison of samples.
The proprietary green-lipped mussel oil (GLM) used in this experiment was sampled from a commercially available capsule (Antinol®) which is a mixture of the pure supercritical fluid extracted mussel oil and olive oil carrier used to assist encapsulation. The capsules tested contained 50 mg of GLM oil and 100 mg of olive oil carrier and 0.025 mg alphatocopherol (vitamin E). By the protocol used in sampling these capsules, the GLM oil was diluted, against EPA and DHA, by a factor of three, and the 250, 500, 1000 μg/mL samples used were actually 83, 167, 333 μg/mL of equivalent GLM oil. As the samples contained twice as much olive oil to GLM oil, it makes sense that these in vitro results could equally be attributed to olive oil. Due to this unfortunate error, the results and conclusions the authors have reached are not valid.
It is important to note that there are in vivo canine trials which demonstrate the clinical effectiveness of Antinol in osteoarthritis (Kwananocha et al., 2016; Mongkon & Soontornvipart, 2012; Soontornvipart et al., 2015) . Further work attempting to elucidate mechanisms of action and the effects of Antinol on cartilage degradation are warranted.
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